Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of developing ...

Pfizer's 14% operational growth in non-COVID products shows the core business is stronger than many believe. The company's ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

With the total return of Pfizer's (NYSE: PFE) shares rising by just 1.9% this year so far, investors may be yearning for some ...

Pfizer's earnings were better than investors and management had anticipated. Its financial projections and forecasting abilities recently came under fire. It also raised its annual guidance, which ...

Pfizer’s revenue from pharmaceuticals declined Pharmaceutical giant Pfizer is getting into the health care delivery business.

Pfizer has beaten analyst estimate both top- and bottom line. The firm has also raised its full-year guidance. Read my ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer now expects between $61 billion and $64 billion in revenue for the year and raised its outlook for adjusted earnings ...

It is a critical quarterly report for Pfizer, which is grappling with a proxy battle waged by the activist investor Starboard Value.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Pfizer (PFE – Research Report) today. The company’s shares ...